Itau Unibanco Holding S.A. Blueprint Medicines Corp Transaction History

Itau Unibanco Holding S.A.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$85.18 - $108.78 $4,259 - $5,439	50 New	50 $5,000
Q4 2023 Feb 14, 2024	SELL	$43.96 - $92.84 $923 - $1,949	-21 Reduced 21.0%	79 $7,000
Q3 2023 Nov 14, 2023	SELL	$46.9 - $66.0 $46 - $66	-1 Reduced 0.99%	100 $5,000
Q2 2023 Aug 14, 2023	SELL	$42.2 - $66.37 $506 - $796	-12 Reduced 10.62%	101 $6,000
Q4 2022 Feb 09, 2023	SELL	$41.06 - $66.48 $369 - $598	-9 Reduced 7.38%	113 $4,000
Q2 2022 Aug 15, 2022	BUY	$45.23 - $70.15 $5,518 - $8,558	122 New	122 $6,000
Q4 2021 Feb 14, 2022	SELL	$94.25 - $115.99 $20,358 - $25,053	-216 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$80.98 - $109.47 $485 - $656	6 Added 2.86%	216 $22,000
Q2 2021 Aug 17, 2021	BUY	$82.78 - $101.0 $17,383 - $21,210	210 New	210 $18,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.47B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Itau Unibanco Holding S.A., based on Form 13F filings with the SEC.

Stay updated on Itau Unibanco Holding S.A. with notifications on news.